Akoya Biosciences Inc AKYA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.29 unchanged at close Jul 8
Last close · Previous close $1.29
- Market cap
- $64.26MAt the Jul 8 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.96Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.29unchangedTue, Jul 8 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.29Jul 7
- Volume0.00Jul 8 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume472.92KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Jul 8 close. Total return includes reinvested dividends.Price change only, without dividends.
| Period | AKYA |
|---|---|
| Short term | |
| 1M | AKYA: up 11.2% |
| 3M | AKYA: up 25.2% |
| YTD | AKYA: down 43.7% |
| 1Y | AKYA: down 38.3% |
| Long term | |
| 3Y | AKYA: down 90.8% −54.9% a year |
$10,000 invested in AKYA a year ago (Jul 8, 2024) would be worth about $6,172 at the close on , with dividends reinvested.
| Period | AKYA |
|---|---|
| Short term | |
| 1M | AKYA: up 11.2% |
| 3M | AKYA: up 25.2% |
| YTD | AKYA: down 43.7% |
| 1Y | AKYA: down 38.3% |
| Long term | |
| 3Y | AKYA: down 90.8% −54.9% a year |
$10,000 invested in AKYA a year ago (Jul 8, 2024) would be worth about $6,172 at the close on , not counting dividends.
All-time high
$26.05
Closing high on . Now 95.0% below that record.
Split-adjusted daily closes since Apr 16, 2021.
Stock splits
AKYA hasn’t split since its price history begins in 2021.
Valuation
The Jul 8 close compared with the last 12 months of reported results (the four quarters to Mar 31, 2025). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$0.96 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 0.8×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - −50.33%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $119.75MAt the Jul 8 close
What it would cost to buy the whole business: the market cap at the Jul 8 close, plus debt, minus cash and short-term investments from the Mar 31, 2025 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own AKYA DCF in Excel. Value Akoya Biosciences with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY25, the quarter ended Mar 31, 2025. “Last 12 months” means the four quarters from Apr 1, 2024 to Mar 31, 2025, and balance-sheet figures are as of Mar 31, 2025.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $79.96Mdown 14.5%
- Net income
- −$47.53M
- Diluted EPS
- −$0.96
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY23 (Jun 30, 2023) | $23.52M | −$20.80M | −$0.51 |
| Q3 FY23 (Sep 30, 2023) | $25.22M | −$12.92M | −$0.26 |
| Q4 FY23 (Dec 31, 2023) | $26.49M | −$10.80M | −$0.20 |
| Q1 FY24 (Mar 31, 2024) | $18.35M | −$23.48M | −$0.48 |
| Q2 FY24 (Jun 30, 2024) | $23.16M | −$13.15M | −$0.27 |
| Q3 FY24 (Sep 30, 2024) | $18.81M | −$10.53M | −$0.21 |
| Q4 FY24 (Dec 31, 2024) | $21.34M | −$8.20M | −$0.16 |
| Q1 FY25 (Mar 31, 2025) | $16.64M | −$15.65M | −$0.32 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $42.44M | −$16.71M | −$9.18 |
| FY21 (Dec 31, 2021) | $54.92M | −$42.94M | −$1.65 |
| FY22 (Dec 31, 2022) | $74.86M | −$70.64M | −$1.87 |
| FY23 (Dec 31, 2023) | $96.63M | −$63.32M | −$1.43 |
| FY24 (Dec 31, 2024) | $81.67M | −$55.37M | −$1.12 |
Margins
- Gross 61.7%
- Operating −48.9%
- Net −59.4%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$32.34MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$30.49MLast 12 months
- Capital spending$1.85MLast 12 months
- −40.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $62.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $28.23MAs of Mar 31, 2025
Cash plus short- and long-term marketable securities on the Mar 31, 2025 balance sheet.
- Total debt$83.72MAs of Mar 31, 2025
- Net debt$55.49MAs of Mar 31, 2025
- 0.61As of Mar 31, 2025
Current assets divided by current liabilities on the Mar 31, 2025 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −505.8%Last 12 months
Over the last 12 months, Akoya Biosciences lost money: its net loss was 505.8% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −37.2%Last 12 months
Over the last 12 months, Akoya Biosciences’s net loss was 37.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Akoya Biosciences Inc
Akoya Biosciences Inc
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
AKYA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
AKYA stock FAQ
What is AKYA stock’s price today?
Akoya Biosciences (AKYA) traded at $1.29 at the close on , unchanged from the previous close of $1.29.
What is Akoya Biosciences’s market cap?
Akoya Biosciences’s market capitalization is about $64.3 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $1.29 (how market cap works). Akoya Biosciences reported 49.82M shares outstanding at the end of its latest quarter ().
What is AKYA’s P/E ratio?
AKYA’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.96).
How much revenue does Akoya Biosciences make?
Akoya Biosciences reported $80.0 million of revenue over the four quarters to , down 14.5% from the twelve months before. In its latest quarter (Q1 FY25, ended ) revenue was $16.6 million, down 9.3% from a year earlier.
Is Akoya Biosciences profitable?
Not over the four quarters to . Akoya Biosciences reported a net loss of $47.5 million across those four quarters on $80.0 million of revenue.
What are AKYA’s earnings per share?
AKYA’s diluted earnings per share were −$0.96 over the four quarters to , compared with −$1.45 in the twelve months before. The latest quarter (Q1 FY25) brought −$0.32 per share, against −$0.48 a year earlier (how EPS works).
Does AKYA pay a dividend?
Akoya Biosciences hasn’t paid a dividend in the last twelve months.
What is AKYA’s all-time high?
AKYA’s highest closing price was $26.05 on , adjusted for stock splits. At $1.29 at the close on , it is 95.0% below that record.
Has AKYA stock ever split?
No. AKYA hasn’t split since its price history begins in 2021.
How has AKYA stock performed?
Including dividends and measured to the close on , AKYA has returned −43.7% so far this year and −38.3% over the past year. Past performance doesn’t predict future returns.
What sector and industry is Akoya Biosciences in?
Akoya Biosciences is in the Healthcare sector and the Medical Instruments & Supplies industry, and is headquartered in Massachusetts, USA.
What exchange does AKYA trade on?
Akoya Biosciences trades on the Nasdaq under the ticker symbol AKYA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.